findmyKOL
Clinical trialNCT05765500RecruitingPhase 2Interventional

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

SponsorDana-Farber Cancer InstituteEnrollment110Prostate CancerProstatic Neoplasms
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label. The names of the study drugs involved in this study are: * Leuprolide (type of ADT) * Relugolix (type of ADT)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

    Not, yet, recruiting
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

    Recruiting
  • Dana-Farber Cancer Institute at Foxborough

    Foxborough, Massachusetts, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Leuprolide →Relugolix →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
12 Feb 2024
Primary completion
1 Jul 2027
Completion
1 Jan 2028
Last update posted
30 Jul 2026
Registered enrollment
110
Registry id
NCT05765500
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.